Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Added to Horizons Marijuana Life Sciences Index ETF

Horizons ETFs Management (Canada) Inc. recently announced completion of its quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF (“HMMJ”). Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is one of 11 new holdings that have been added to HMMJ’s portfolio, which is the world’s first ETF … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Added to Horizons Marijuana Life Sciences Index ETF”

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Utilizes Proprietary Advanced Biosynthesis Process to Develop Cannabinoids-based Therapies

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) remains focused on discovering potential breakthrough cannabinoid-based therapies by utilizing its proprietary cannabinoid biosynthesis process and its bioinformatics drug and disease targeting tool. An article discussing this reads: “Other biopharmaceutical companies may produce cannabinoids in the laboratory using chemical synthesis, but there’s a litany of drug development efforts with … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Utilizes Proprietary Advanced Biosynthesis Process to Develop Cannabinoids-based Therapies”

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Featured in Visual Capitalist Company Spotlight

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) was recently highlighted in a company spotlight article by Visual Capitalist. The article features an infographic that breaks down the company’s development of novel cannabinoid-based therapies from start to finish. Among other areas of interest, Visual Capitalist provided an in-depth look into InMed’s Bioinformatics … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Featured in Visual Capitalist Company Spotlight”

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Presenting at Cannabis-Based Science & Medicine Conference

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) this morning said that it will be presenting twice at the Biopharma Forum on ‘Cannabis-Based Science & Medicine’ conference. The company will present on Thursday, November 30 and Friday, December 1 at the conference taking place in Denver, CO. The company’s chief scientific officer, Dr. Sazzad Hossain, will be … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Presenting at Cannabis-Based Science & Medicine Conference”

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Unlocks Ability to Produce 90+ Cannabinoids through Biosynthesis

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues to advance its drug development programs through the use of its proprietary bioinformatics database assessment tool. An article discussing this reads: “InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Unlocks Ability to Produce 90+ Cannabinoids through Biosynthesis”

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Highlights Positive Pre-Clinical Data Related to Biosynthesis Platform

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced results from a study co-sponsored by InMed and the University of British Columbia. Notably, this study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye resulting in enhanced drug uptake via the cornea and lens. “Importantly, this … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Highlights Positive Pre-Clinical Data Related to Biosynthesis Platform”

InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) Biosynthesis Technology Demonstrates Robust Diversity

Biosynthesis technology making strong advances Two promising pipeline candidates Inclusion in the CSE25 Index InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://nnw.fm/tP4jS). The company recently announced it has enabled the production of all four “gateway” cannabinoids using genetically engineered microorganisms. … Continue reading “InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) Biosynthesis Technology Demonstrates Robust Diversity”

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on INM-405 Development

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced preclinical results in the development of INM-405 for the treatment of pain. Notably, results from the company’s studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on INM-405 Development”

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Addition of Dr. Mauro Maccarrone to Scientific Advisory Board

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the addition of Dr. Mauro Maccarrone to its scientific advisory board. Maccarrone is professor and chair of biochemistry and molecular biology at Campus Bio-Medico, University of Rome. He also serves as director of the Laboratory of Lipid Neurochemistry of the European … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Addition of Dr. Mauro Maccarrone to Scientific Advisory Board”

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Paving the Way as Biosynthesis Promises to Revolutionize Drug Development

Forbes predicts medical marijuana sales to reach $13.3 billion by 2020 Biotech/pharma market could surpass $20 billion by 2020, per estimates from Viridian Capital Advisors InMed’s biosynthesis process uses DNA and E. coli to produce cannabinoids that are identical to the 90+ found in nature The company’s pipeline drugs, focusing on rare dermatological diseases, glaucoma … Continue reading “InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Paving the Way as Biosynthesis Promises to Revolutionize Drug Development”

Contact us: 212.418.1217